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ABSTRACT 
Tumour hypoxia is widely recognised as a major cause of treatment failure and poor 
outcome for a variety of malignancies. Tumour hypoxia also results in resistance to 
conventional anticancer therapies leading to an increase in malignancy and metastases to other 
sites, in particular, the bone. Bone metastases occur in more than 75% of patients with breast, 
prostate and lung cancer. Tumours in the bone are often resistant to anticancer therapy due to 
the hypoxic nature of the bone micro-environment, resulting in their recurrence and 
metastasis. 
Hypoxia also offers treatment opportunities, exemplified by the development of highly 
active compounds that target hypoxic zones known as Hypoxia Activated Pro-drugs. 
Evofosfamide is a hypoxia activated pro-drug created by the conjugation of 2-nitroimidazole 
to bromo-isophosphoramide (Br-IPM). When Evofosfamide is delivered to regions of 
hypoxia, Br-IPM, the DNA cross linking toxin is released resulting in cancer cell death. 
The cytotoxic activity of evofosfamide against osteosarcoma cells was assessed in 
vitro and its anticancer efficacy as a single agent and in combination with doxorubicin was 
evaluated in an orthotopic mouse model of human osteosarcoma (OS). In vitro, evofosfamide 
was cytotoxic to osteosarcoma cells selectively under hypoxic conditions, whereas primary 
normal human osteoblasts were protected. Animals transplanted with OS cells directly into 
their tibiae and left untreated developed mixed osteolytic/osteosclerotic bone lesions and 
subsequently developed lung metastases. Evofosfamide reduced tumor burden in bone and 
cooperated with doxorubicin to protect the bone from osteosarcoma induced bone destruction, 
while also reducing lung metastases. 
XI 
In addition, under hypoxic conditions in vitro, evofosfamide cooperated with Pro 
Apoptotic Receptor Agonists (PARAs) dulanermin and drozitumab, resulting in a dose-
dependent increase in cytotoxicity to osteosarcoma cells selectively under hypoxic conditions. 
In contrast primary normal human osteoblasts under the same hypoxic conditions were 
resistant. In vivo, evofosfamide cooperated with drozitumab, reducing tumor burden in the 
orthotopic mouse model of human osteosarcoma and protected the bone from osteosarcoma-
induced bone destruction while also reducing the growth of pulmonary metastases. 
In order to assess the anticancer efficacy of evofosfamide against breast cancer, a 
panel of human breast cancer cell lines were treated with evofosfamide and shown to be 
highly cytotoxic under hypoxia. Osteolytic MDA-MB-231-TXSA cells were transplanted into 
the mammary fat pad or into the tibiae of mice, allowed to establish and treated with 
evofosfamide, paclitaxel, or both. In vivo evofosfamide demonstrated tumor suppressive 
activity as a single agent and cooperated with paclitaxel to reduce mammary tumor growth. 
Breast cancer cells transplanted into the tibiae of mice developed osteolytic lesions. Treatment 
with evofosfamide or paclitaxel resulted in a significant delay in tumor growth and with an 
overall reduction in tumor burden in bone, whereas combined treatment resulted in a 
significantly greater reduction in tumor burden in the tibia of mice. 
In conclusion the preclinical data presented in this thesis demonstrate that 
evofosfamide may be an attractive therapeutic agent when used alone and in combination with 
chemotherapy or PARAs for the treatment of osteosarcoma and breast cancer. 
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Hypoxia and Cancer 
An important limitation to current cancer therapy is the cellular environment within 
solid tumours. This microenvironment has subregions of nutrient deprivation, low 
extracellular pH, high interstitial fluid pressure and hypoxia (Kaisa R Luoto1†, 2013). 
Hypoxia is a factor which is present within nearly all cancer types and plays a central role in 
cancer progression. The vasculature within most solid tumours consists of poorly functional 
and abnormally formed blood vessels that are unable to deliver enough oxygen and nutrients 
to support the rapidly growing tumour mass. This reduction in oxygen is lethal to some cancer 
cells resulting in necrotic regions within the tumour, but some cancer cells adapt and survive 
the low oxygen conditions (Bennewith & Dedhar, 2011). 
These hypoxic cancer cells evade most anticancer drugs, because hypoxic cells reside 
some distance away from blood vessels, therefore conventional chemotherapy, which is 
administered systemically, cannot reach these cells. Most antitumor agents cannot penetrate 
more than 50-100 M from capillaries, which leads to cytotoxic concentrations not being 
attained in hypoxic regions. Cellular proliferation also decreases partly due to hypoxia and 
cells in this hypoxic environment have lower sensitivity to p53 mediated apoptosis. In 
summary, tumours in the hypoxic environment have a more malignant phenotype, have 
increased rates of mutations and they express genes which are associated with angiogenesis, 
tumour invasion and anticancer resistance. These tumour cells are also highly metastatic 
(Graeber et al., 1996). Therefore, the presence of hypoxic regions within the tumour is a major 
cause of treatment failure and poor outcome for a wide variety of malignancies. 
In addition, an important transcriptional factor involved in the resistance of cancer 
cells in the hypoxic environment is the stabilization of Hypoxia Inducible Factor 1 (HIF-1). 
HIF-1 is the transcriptional factor that is essential in the response of cells to hypoxia and is a 
key regulator in oxygen homeostasis (Maxwell, 2004). HIF-1α is the molecule that is 
constantly present in normoxic conditions and under these conditions, this molecule is 
regulated post transcriptionally by prolyl hydroxylases via hydrolysis and is constantly 
degraded. This hydrolysisis inhibited under hypoxia, resulting in the accumulation HIF-1α 
instantaneously and translocating to the nucleus (Semenza, 2004). Heterodimerization of HIF-
1 and HIF-1(which is constantly expressed in both normoxic and hypoxic conditions) 
subunits result in the formation of the HIF-1 protein, activating the transcription of specific 











Fig.1. Squamous cell carcinoma (×40) showing hypoxia staining in brown (pimonidazole 








HIF-1 regulates more than 70 genes which are involved in cellular adaptation to 
hypoxia (Semenza, 2004), including Lysyl oxidase, Carbonic anhydrase 9, Chemokine 
receptor 4, Facilitated glucose transporter 1 and VEGF. This stabilization of HIF-1 adds to the 
adaption capability of cancer cells to the hypoxic tumour environment and also leads to the 
resistance of cancer cells to conventional chemotherapeutic drugs and radiotherapy. 
 
The Bone Micro-environment 
Bone is made up of both trabecular (spongy) and cortical (solid) bone and these 
compositions are constantly being remodelled in order to maintain skeletal integrity. Within 
these bone types there are two categories of bone cells. The first category of bone cells is 
made up of osteoblasts, osteocytes and endosteal cells. Osteoblasts are derived from the 
mesenchymal lineage (Rauner, Stein, & Hofbauer, 2012) and synthesize proteins that form the 
organic matrix of bone. Osteoblasts control the mineralisation of bone and have receptors for 
hormones such as vitamin D, estrogen glucocorticoids, leptin and the parathyroid hormone. 
When osteoblasts finish making new bone they become surrounded with matrix and 
differentiate into osteocytes or they remain on the surface of new bone and differentiate into 
lining cells (Rauner, Stein & Hofbauer 2012). 
Osteocytes exist inside the bone and have long branches to allowing contact with each 
other and lining cells. Osteocytes secrete various factors that activate, osteoblasts, osteoclasts 
or lining cells which then remodel bone (Bonewald, 2011). The lining cells cover the surface 
of the bone and have receptors for hormones and other factors that can initiate bone 
remodelling (Miller, de Saint-Georges, Bowman, & Jee, 1989), thereby acting as a blood-bone 
barrier while still having the ability become osteoblasts upon exposure to the parathyroid 
hormone or mechanical forces (Clarke, 2008). 
The second category of bone cells are osteoclasts which are multinucleated cells 
derived from the hematopoietic lineage that dissolve and resorb bone. Osteoclasts are derived 
from monocytes which become osteoclast precursor cells and are transformed into osteoclasts 
when RANK (‘receptor activator of NF-kB’) is activated by RANK-ligand on osteoclast 
precursor cells. RANK-ligand is a member of the TNF family which is secreted by osteoblasts 
and stromal cells (Lacey et al., 1998). 
Osteoprotegerin (OPG) is also produced by osteoblasts, it binds with and neutralises 
RANK-ligand and is involved in inhibiting osteoclast activation and function (Simonet et al., 






















Fig.2. Normal bone remodelling. Osteoblasts and stromal cells produce RANKL which 
binds to the RANK receptor on pre-osteoclasts, stimulating their differentiation and 
maturation into functional osteoclasts. However OPG, also produced by osteoblasts binds 
to RANKL, inhibiting the association between RANKL and RANK, therefore inhibiting 
osteoclast formation (Kohli & Kohli, 2011). 
6 
In addition the bone is a hypoxic micro-environment. Hypoxia regulates normal 
marrow haemopoiesis and mesenchymal differentiation. This is achieved by hypoxia 
stimulating the formation and activation of cells which have been generated from marrow 
precursors, including cells of the monocyte–macrophage lineage. The medullary cavity 
oxygen pressure in humans is estimated to be 5% O2 (Asosingh et al., 2005) and the bone 
tissue has oxygen levels that range between 1-7%. Recent studies have also shown that 
hypoxia blocks the growth and differentiation of osteoblasts, while stimulating osteoclast 
formation (Arnett, 2010). 
This balance of bone formation and bone resorption resulting from the interaction of 
these cells in the hypoxic bone environment can be altered due to a variety of bone diseases 
including osteosarcoma and metastatic breast cancer. 
 
The Vicious Cycle of Bone Cancer 
Bone is a preferred site for breast and prostate cancer metastasis in patients with late 
stage disease. Cancer within the bone forms two types of lesions. Osteolytic lesions, which are 
caused by excessive osteoclast activity in relation to osteoblast bone formation, resulting in 
net bone loss. The second type, osteosclerotic lesions are caused by an increase of osteoblastic 
activity in relation to osteoclast resorption. This leads to an increase in disorganised bone 
formation. In most patients, cancers in the bone are characterised by a combination of both, as 
the processes of bone resorption and bone formation are linked but distorted in cancer 
(Mundy, 2002a). 
This imbalance of bone remodelling caused by cancer creates a ‘vicious cycle’, where 
bone resorption is induced by the tumour, causing the release growth factors from the bone 
matrix. This further promotes tumour growth, leading to increases of pro-resorptive factors, 
which further break down bone (Ooi, Zheng, Stalgis-Bilinski, & Dunstan, 2011). The vicious 
cycle is largely osteolytic, leading to a variety of SREs which include bone pain, 
hypercalcaemia, pathological fractures, spinal cord and nerve compressions, these 
complications lead to a diminished quality of life and ultimately death in these patients caused 
by metastases to other sites in the body such as the lung, liver and brain (R. E. Coleman, 
1997). 
The bone matrix is rich in growth factors such as transforming growth factor-β (TGF-
β) and insulin growth factors (IGFs). These growth factors are released during osteolysis 
caused by osteoclast activity, further stimulating tumour cell proliferation. 
7 
Metastatic cells in the bone environment, in particular breast cancer cells secrete 
parathyroid hormone-related protein (PTHrP). PTHrP increases osteoblast production of 
RANKL, which stimulates osteoclast formation and activity, resulting in an increase in bone 
resorption, releasing more growth factors such as TGF-β and IGFs from the bone and 
ultimately maintaining this vicious cycle. TGF-β also increases hypoxic signalling by 
inhibiting prolyl hydroxylase 2 resulting in the decrease in HIF-1α degradation which 
stabilises HIF-1 and results in the transcription of HRE genes. 
Bone itself is a hypoxic environment, with oxygen levels ranging between 1-5% O2 
(Asosingh et al., 2005). Cancer cells that survive in this hypoxic bone environment proliferate 
and participate in this vicious cycle of bone destruction (Kingsley, Fournier, Chirgwin, & 
Guise, 2007). Hypoxia is usually accompanied by an increase in acidity in the bone which 
also has significant effects on bone remodelling. Extracellular acidification increases 
osteoclast activity leading to bone resorption, while osteoblast mineralisation is inhibited by 
acidic pH (Brandao-Burch, Utting, Orriss, & Arnett, 2005). Bone destruction also leads to 
increase in calcium levels which also promote tumour growth and the production of PTHrP. 
Therefore this bone microenvironment consists of numerous factors, such as hypoxia, 
acidosis, extracellular calcium, and growth factors which all combine to drive this vicious 






































Fig.3. The Vicious Cycle of Bone Cancer. Tumour cells produce factors such as PTHrP that 
promote the formation and activation of osteoclasts. Osteoclast activation results in bone 
resorption and thus release of factors from the bone matrix, such as TGF-β, IGFs and Ca
2+
 







Osteosarcoma is a cancer derived from primitive bone-forming mesenchymal cells and 
is the most common primary bone cancer and the eighth most common tumor in children and 
adolescents (Ottaviani & Jaffe, 2009). Osteosarcoma can occur in any bone, but the most 
common sites are the femur, the tibia and the humerus (Chou & Gorlick, 2006). Bone lesions 
caused by osteosarcoma are characterized on the basis of their radiologic appearance and 
present as either osteolytic which results in net bone loss, osteoblastic (osteosclerotic) which 
results in highly disorganised bone formation, or mixed (Mundy, 2002a). Metastatic spread 
from the bone is preferential to the lungs and is seen in 20% of osteosarcoma patients which is 
correlated with poor survival (Link et al., 1991; Saeter et al., 1997). 
Current treatment of osteosarcoma includes approximately 10 weeks of preoperative 
chemotherapy comprised of doxorubicin, cisplatin and high dose methotrexate, followed by 
surgery which involves the removal of the primary tumour and if present, all sites of the 
metastatic disease. After surgery patients receive 20 weeks of maintenance chemotherapy with 
the same 3 agents (Stefano Ferrari et al., 2012). Following this treatment, a 5 year survival 
rate for non-metastatic osteosarcoma is 70% (Akiyama, Dass, & Choong, 2008). However if 
metastatic osteosarcoma disease is detected at the time of initial diagnosis, then this leads to 
poor prognosis, with long term survival rates between 10-40% (Kager et al., 2006). Therefore 




Breast Cancer is the most common malignancy and the leading cause of cancer 
mortality in women worldwide. It occurs in 1 out of 9 women and accounts for 23% of the 
total new cases of cancer and 14% of the total cancer deaths in 2008 worldwide (Ferlay et al., 
2010; A. Jemal et al., 2011). It is also estimated that worldwide, over 508000 women died in 
2011 due to breast cancer (Metin Seker et al., 2014). The incidence of breast cancer is 
increasing in the developing world due to increase life expectancy, increase urbanization and 
adoption of western lifestyles (Hery, Ferlay, Boniol, & Autier, 2008). In contrast, breast 
cancer death rates have been decreasing in developed countries for the past 25 years, largely 
as a result of early detection through the wide spread use of mammography, an increase in 
breast cancer awareness and improved treatment by chemotherapy, hormone targeted therapy 
and more recently drugs that target the cancer’s specific proteins, genes or tissue environment 
(DeSantis et al., 2015; Ahmedin Jemal, Center, DeSantis, & Ward, 2010). 
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Treatment depends upon tumor size, the number and location of the lymph nodes 
involved, the presence or absence of distant metastatic disease and pathologic features such as 
receptor status and tumor grade (Moulder & Hortobagyi, 2008). Early stage breast cancer is 
often treated using local therapy. Local therapy can include breast conserving surgery or 
mastectomy which is followed by radiotherapy. More advanced breast cancer requires 
systemic therapy that can reach cancer cells anywhere in the body. Types of systemic therapy 
used to treat breast cancer include the use of chemotherapeutic agents such as paclitaxel, 
doxorubicin, cyclophosphamide, carboplatin and 5-fluorouracil, which are given to patients in 
various combinations (Guarneri & Conte, 2004). In addition, the use of hormone therapeutic 
drugs such as tamoxifen can specifically target breast cancer types that require estrogen and 
progesterone to fuel their growth, due to their estrogen and progesterone receptor positivity. 
Advances in targeted therapy have also improved patient outcomes. Therapeutic targeting 
drugs target specific changes to breast cancer cells which are different from normal cells, such 
as HER2 targeted therapy, which target breast cancer cells that are HER2 positive (Arteaga et 
al., 2012). 
Current treatment options for the treatment of the early stages of breast cancer have 
been very effective in prolonging survival and improving the quality of life in women 
diagnosed with early breast cancer. However despite the significant improvements in 
detecting and treating the early stages of breast cancer 30% of women diagnosed with early-
stage breast cancer, will eventually have locally advanced or metastatic breast cancer. 
 
Breast Cancer and Bone Metastasis 
Patients diagnosed with advanced breast cancer experience poor prognosis and as a 
result the 5 year survival rate is reduced to 20% (Beaumont & Leadbeater, 2011). The low 
survival rate is not due to the cancer at the primary site, but the result of the subsequent 
metastasis to secondary sites in the body, most common site being the skeleton. 
An estimated 80% of patients with advanced breast cancer develop skeletal metastasis 
(R. E. Coleman, 2006; Siegel, Ward, Brawley, & Jemal, 2011). Bone metastases result in 
various pathological complications that can result in patients experiencing debilitating skeletal 
related events (SREs). These SREs include pathological skeletal fractures, hypercalcaemia 




SREs such as fractures have become less frequent with bisphosphonate therapy which 
blocks bone destruction by inhibiting the formation of osteoclasts (Ganz & Stanton, 2015), 
however, patients still suffer from severe bone pain and loss of mobility which eventually 
leads to reduction of quality of life and survival (Robert E. Coleman, 2012). 
These SREs arise because breast cancer cells that metastasize to the bone disrupt 
normal bone remodeling which leads to extensive bone destruction. Most patients with late 
stage metastatic breast cancer receive chemotherapy which includes taxanes (paclitaxel), 
anthracyclines (doxorubicin), hormone therapy and sometimes surgery (DeSantis et al., 2014). 
However, due to high toxicity and the development of drug resistance, such anticancer 
treatments are often discontinued and in patients with advanced disease in particular where the 
cancer has metastasized to the bone, the treatment becomes only palliative. 
 
Hypoxia Activated Pro-drugs (HAPs) 
Prodrugs that are enzymatically converted within tumours to active metabolites have 
been of particular interest for selective cancer therapy. HAPs have been investigated for the 
treatment of cancer for over 30 years and exploit a generic feature that differentiates tumours 
from normal tissue, potentially overcoming the resistance that hypoxic tumours have to 
conventional chemotherapy and radiotherapy. HAPs that have been evaluated in various 
stages of clinical trials but have been discontinued include Tirapazamine (3-amino-1,2,4-
benzotriazine 1,4-dioxide; SR 4233) which under hypoxic conditions is bioreduced to a 
nitroxide-base free radical that removes hydrogen from DNA strands causing DNA damage. 
When tirapazamine was used in combination with cisplatin and with radiotherapy in phase 3 
clinical trials, it did not improve overall survival in patients with advanced head and neck 
cancer (NCT00094081). In addition these combinations led to an increase in toxicities which 
caused nausea, diarrhoea, vomiting, myalgia, and muscle spasms (Wu et al., 2012). 
PR-104 is a water soluble phosphate ester that gets converted to the corresponding 3,5-
dinitrobenzamide mustard prodrug, PR-104A. Nitroreduction of PR104A leads to the 
formation of the cytotoxic hydroxylamine (PR104H) and amine (PR104M) by crosslinking 
DNA which is determined by hypoxia, relevant oxidoreductases and the functional status of 
DNA repair pathways in the cell (Christopher P. Guise et al., 2012). PR-104 has also been 
discontinued after phase I studies for the treatment of numerous solid tumour types resulted in 
myelotoxicity in 2 out of 3 patients in the study (NCT00349167). In addition PR-104 as a 
monotherapy also caused myelotoxicity and grade four thrombocytopenia (NCT00459836) 
(McKeage et al., 2012). 
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The HAP AQ4N (banoxantrone; 1,4-bis((2-(dimethylamino)-N-ethyl)amino)-5,8-
dihydroxyanthracene-9,10-dione)  is nontoxic until bioreduced in hypoxic cells by a number 
of cytochrome P450 isozymes (CYP) or inducible nitric oxide synthase (NOS2A)  in tumours 
to form the short  term mono-N-oxide intermediate AQ4M, which then becomes the cytotoxic 
ditertiary cationic amine AQ4 (Manley & Waxman, 2013). AQ4 then intercalates DNA and 
inhibits toposomerase 2 (C. P. Guise et al., 2013). Phase I clinical studies investigating the 
HAP Banoxantrone (AQ4N) against solid malignancies and Non-Hodgkin’s Lymphoma 
(NCT00090727) have also been terminated. Among the most common adverse events 
observed by the administration of AQ4N in Phase I clinical trials were fatigue, diarrhoea, 
nausea, vomiting, and anorexia (Albertella et al., 2008; Papadopoulos et al., 2008). 
Evofosfamide (TH-302) and Tarloxotinib bromide (TH-4000) which is a prodrug that 
selectively releases a covalent (irreversible) EGFR tyrosine kinase inhibitor under hypoxic 
conditions are still in clinical trials, of which evofosfamide is the most advanced as well as 
































Fig.5. Chemical structures of PR104,  its converted form PR-104A and reduced cytotoxic 
















Fig.4. Chemical structure of tirapazamine (Francis W. Hunter et al., 2012). 
Fig.6. Chemical structures of AQ4N its intermediate AQ4M and reduced cytotoxic amine AQ4 
(Loadman, Swaine, Bibby, Welham, & Patterson, 2001). 
Fig.7. Chemical structure of tarloxotinib bromide and its 1e- reduction resulting in the 
EGFR/HER2 tyrosine kinase inhibitor being released under hypoxic conditions (Stephen V 
Liu & Stew Kroll, 2016). 
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Evofosfamide 
Evofosfamide is a 2-nitromidazole-linked prodrug of a brominated version of the 
cytotoxin bromo-isophosphoramide mustard (Br-IPM) developed by Threshold 
Pharmaceuticals. The 2-nitromidazole functional group of evofosfamide is attracted to 
hypoxic conditions and acts as a hypoxia activated trigger under these conditions, releasing 
Br-IPM into the hypoxic environment. Br-IPM acts as a DNA crosslinking agent which is able 
to kill both dividing and non-dividing cells in this hypoxic environment. 
Evofosfamide also has a ‘bystander effect’, where once activated evofosfamide can 
also diffuse into normoxic areas to act against neighbouring cells in the normoxic regions 
within the tumour. Hypoxia activation of evofosfamide occurs when the 2-nitromidazole 
portion of evofosfamide undergoes electron rearrangement forming a radical anion under 
hypoxia and then fragments releasing the toxic bromo-isophosphoramide mustard which 
diffuses into the hypoxic tumour (Meng et al., 2012). However under normoxic conditions, 
evofosfamide is converted into the radical anion and then back oxidized into its pro-drug form 
in a futile cycle generating superoxides from the reduction of oxygen (Fig.6). These 
superoxides react with free hydroxyl radicals which act as oxidants that can also damage DNA 
(Keyer & Imlay, 1996). 
Evofosfamide showed encouraging data in phase II clinical trials for the treatment of 
metastatic or locally advanced unresectable soft tissue sarcoma with doxorubicin and for the 
treatment of pancreatic ductal adenocarcinoma with gemcitabine. Unfortunately phase III 
studies did not achieve primary overall endpoints in combination with chemotherapy for the 
treatment of soft tissue sarcoma (NCT01440088) and metastatic pancreatic adenocarcinoma 
(NCT0174679). These phase III results have led to the termination and withdrawal of a 
number of phase II trials such as the treatment of oesophageal cancer (NCT02598687), non-
squamous non-small cell lung cancer (NCT02093962), liver cancer (NCT01497444), soft 
tissue sarcoma (NCT02255110) and pancreatic cancer (NCT02047500, NCT02496832). 
However evofosfamide is still being investigated in phase II trials for multiple 
myeloma (NCT01522872), high grade astrocytoma (NCT01403610), metastatic 
neuroendocrine pancreatic tumours (NCT02402062), metastatic melanoma (NCT01864538) 
and advanced biliary tract cancer (NCT02433639). Phase I trials include solid tumours 




The strategy of hypoxia-targeted treatment with evofosfamide in the hypoxic bone 
marrow has been tested in preclinical studies of multiple myeloma (Jinsong Hu et al., 2010; J. 
Hu et al., 2013) and acute myeloid leukaemia (Benito et al., 2015). 
These preclinical studies investigating the anticancer efficacy of evofosfamide against 
multiple myeloma have provided support for the currently active phase II clinical trial to 
evaluate evofosfamide and dexamethasone, with or without bortezomib, or pomalidomide for 
the treatment of patients with relapsed/refractory multiple myeloma (NCT01522872).  The 
preclinical data investigating evofosfamide for the treatment of acute myeloid leukaemia also 
provides support for the future clinical assessment of evofosfamide in the treatment of various 
leukaemia types, following the recent completion of the phase I study (NCT01149915), which 
determined the maximum tolerated dose, dose limiting toxicity, safety and tolerability of 
evofosfamide in patients with various types of advanced leukaemias (Badar et al., 2016). 
To date, there has been no investigation of evofosfamide or any other HAP for the 
treatment of solid tumours that originates or metastasizes to the bone. These previous studies, 
which investigate the role of evofosfamide against multiple myeloma and leukaemia provide 
supporting evidence that targeting the hypoxic bone microenvironment niche with the HAP 


















Fig.8. Chemical structure of evofosfamide and its 1e- reduction resulting in the bis-alkylator 






The Apoptotic Pathways 
Apoptosis is the major mechanism to eliminate damaged cells via programmed cell 
death. It can be stimulated by a variety of factors including developmental cues, cellular stress 
or damage to cellular components caused by radiation, heat shock, infection, oncogenic 
tranformation and cytotoxic drugs (Fadeel, Orrenius, & Zhivotovsky, 1999). The deficiency in 
apoptosis is one of the key hallmarks in cancer (Hanahan & Weinberg, 2000). Two pathways 
induce apoptosis in mammalian cells, firstly the intrinsic pathway, which is activated by 
intracellular processes and depends on the mitochondrion releasing proapoptotic factors. 
Secondly, the extrinsic pathway, which receives signals through the binding of extracellular 
protein ligands to proapoptotic death receptors which are located on the cell surface 
(Gonzalvez & Ashkenazi, 2010). 
Both pathways stimulate pro-apoptotic caspases which are a family of cysteine 
proteases that exist as procaspases. Activation of these procapspases is known as ‘the caspase 
cascade’. Apoptosis is firstly stimulated by the initiator caspases (caspase-8,-9,-10) which 
then activate the effector caspases (caspase-3,-6-7) by proteolytic processing. These effector 
caspases then process cellular proteins, which lead to the unique features of apoptosis such as 




































Fig.9. The intrinsic and extrinsic apoptotic pathways. These two pathways are also 
known as the “death receptor” and the “mitochondrial pathway” respectively. Caspase 8 is 
the initiator caspase of the death receptor pathway, and cleavage of bid results in 
cytochrome c being released from the mitochondrion. Both pathways activate the effector 






mitochondrial pathway, different signals directly stimulate cytochrome c release from the 
mitochondria, which activated the initiator caspase 9 along with the Apaf-1. The downstream 
effects are common in both pathways, activation of the effector caspases (Torok & Gores, 2004). 
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Pro-Apoptotic Receptor Agonists (PARAs) 
ProApoptotic receptor Agonists dulanermin and drozitumab can induce apoptosis 
selectively in cancer cells in vitro and in vivo and as a result have demonstrated anticancer 
efficacy in numerous preclinical studies. Both dulanermin (Apo2L/TRAIL/TNFSF10) and 
drozitumab target the extrinsic apoptotic pathway of cancer cell death, whereas most 
conventional anticancer therapies stimulate apoptosis via the intrinsic pathway. Inactivation of 
p53 in this intrinsic pathway is the most common mutation that allows cancer cells to become 
resistant to apoptosis (Ashkenazi & Herbst, 2008). By focusing on the extrinsic pathway these 
new compounds may overcome cancer cell resistance to chemotherapy. 
Dulanermin activates apoptosis through death domain containing receptors DR4 
(TNFRSF10A/TRAILR1) and DR5 (TNFRSF10B/TRAILR2). In addition, dulanermin also 
interacts with decoy receptors known as DcR1 (TNFRSF10C/TRAILR3), DcR2 
(TNFRSF10D/TRAILR4) and Osteoprotegerin (TNFRSF11B/OPG) which do not transmit 
apoptotic signals. However the expression of DcR1 and DcR2 determines which cells undergo 
apoptosis (Pan, Ni, Yu, Wei, & Dixit, 1998). Dulanermin selectively triggers apoptosis in 
tumor cells over normal cells, which highlights its potential as a therapeutic drug in cancer 
treatment. 
Dulanermin has been tested in phase I and II clinical trials in patients with range of 
cancer types including advanced solid and hematologic tumours, alone or in combination with 
traditional chemotherapy. Dulanermin was well-tolerated by all patients, and most of the 
studies reported some partial responses or stable disease (Amarante-Mendes & Griffith, 
2015). However, dulanermin did not demonstrate significant clinical efficacy when it came to 
complete responses. One possible explanation is the short bioavailability of 30 minutes 
(Ashkenazi et al., 1999) and its inability to bind to death-inducing TRAIL receptors, 
preferring to bind with the decoy TRAIL receptors in various cancer types. 
As an alternative to dulanermin, drozitumab is a fully human agonistic monoclonal 
antibody that specifically binds to and activates DR5 in the same manner as Apo2L/TRAIL (I. 
Zinonos et al., 2009). Drozitumab has a half-life ranging from several days to weeks and has 
been developed to specifically target DR5 (Ashkenazi, 2008a) and not the TRAIL decoy 
receptors. In addition, circulating Fragment Crystalline Gamma (Fcγ) receptors expressed on 
the surface of various immune cells, crosslink with drozitumab which leads to enhanced 
antibody-dependent, cell-mediated cytotoxicity (ADCC) (Wilson et al., 2011), resulting in 
immune cell activation leading to recruitment of other Fcγ receptor expressing cells to the 
tumor microenvironment. 
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The apoptotic tumor cells are then phagocytosed by the activated Fcγ receptor 
expressing immune cells (Takeda et al., 2004), further enhancing the cytotoxic activity of 
drozitumab against cancer. 
Drozitumab has undergone phase I and II clinical trials for the treatment of colorectal 
cancer and advanced tumours (Lemke, von Karstedt, Zinngrebe, & Walczak, 2014). 
Drozitumab was well tolerated with minimal adverse events. Despite the favourable safety 
profile, patients receiving drozitumab in clinical trials receive only minor benefit from 
treatment (Micheau, Shirley, & Dufour, 2013). 
 
PARAs in bone 
In the context of bone related malignancies, the anticancer efficacy of PARAs has 
been evaluated in bone cancer therapy. Preclinically, Apo2L/TRAIL and drozitumab reduce 
tumour burden in bone and limit cancer-induced bone destruction in murine intratibial models 
of metastatic breast cancer and multiple myeloma without compromising normal bone 
metabolism (Agatha Labrinidis et al., 2009; Thai et al., 2006; I. Zinonos et al., 2009). 
However some tumours exhibited or acquired resistance to PARAs-induced apoptosis and 
prolonged treatment failed to completely eradicate tumours from the bone, giving rise to late 
recurrence in both a myeloma and a breast cancer model. The basis for this resistance is not 
well understood, with multiple mechanisms proposed (Ashkenazi, 2015; Ashkenazi & Herbst, 
2008; Bouralexis et al., 2003; Agatha Labrinidis et al., 2009). 
Therefore additional agents such as HAPs can potentially resensitize cancer cells in the 
bone to PARAs and as yet, there have been no clinical trials investigating PARAs in the 
treatment of primary or metastatic bone tumours (Picarda, Trichet, Teletchea, Heymann, & 
Redini, 2012). 
Conventional chemotherapeutic drugs have a significant effect on bone health and 
patients who have received certain chemotherapeutics are at an increased risk for developing 
osteoporosis due to the toxicities to cells of the bone marrow. Preclinical studies show that 
PARAs have no effect on normal bone metabolism (A. Labrinidis et al., 2008). Therefore, the 
combination of HAPs and PARAs should provide great efficacy in the elimination of cancer 
in the bone and metastasis, with the additional advantage that this combination should be non-




Selective targeting of hypoxic tumour cells with the Hypoxia Activated Pro-drug 
evofosfamide in combination with conventional chemotherapeutic agents and Pro-Apoptotic 
Receptor Agonists (PARAs) is an effective approach to eliminate cancer in bone, with 
minimal toxicity to normal bone metabolism. 
 
Aims 
Aim 1: To evaluate the anticancer efficacy of the hypoxia activated pro-drug evofosfamide, 
alone and in combination with doxorubicin against osteosarcoma using both in vitro and in 
vivo systems. 
Aim 2: To evaluate the anticancer efficacy of the hypoxia activated pro-drug, evofosfamide 
alone and in combination with paclitaxel against breast cancer using both in vitro and in vivo 
systems 
Aim 3: To evaluate the anticancer efficacy of the hypoxia activated pro-drug, evofosfamide, 
alone and in combination with Pro-Apoptotic Receptor Agonists against osteosarcoma using 
both in vitro and in vivo systems 
 
Significance and contribution to the discipline 
Bone metastases occur in more than 75% of patients with late stage breast, prostate 
and lung cancer. Cancer in bone is often associated with bone destruction, which causes 
considerable morbidity and reduced quality of life (R. E. Coleman, 1997). Bone destruction 
caused by primary and metastatic cancer leads to bone pain, paralysis due to spinal cord 
compression, hypercalcaemia, fractures and the need for extensive orthopaedic surgical 
intervention (Mundy, 2002a). The cost of this morbidity is enormous, especially since patients 
with cancer in the bone often survive for a longer time than patients with visceral metastases.  
Data from this thesis will raise the possibility that HAPs may be potential therapeutic 
targets in combination with conventional therapeutic strategies and PARAs against tumour 
progression which gives hope of eradicating the tumour completely. Adding to this, the thesis 
will provide important information for future clinical trials of evofosfamide and PARAs in the 
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Appendix: Supplementary Figures 
 
Supplementary Figure 1: 
Activity of TH-302 against OS cells in vitro: A. OS Cell lines MG-63, SAOS and SJSA-1 
were seeded in 96 well plates at 1×10
4
 cells per well and treated with TH-302 in normoxia 
(21% O2) and of hypoxia (1% O2) for 24 hours. TH-302 exhibited dose dependent cytotoxicity 
in hypoxic conditions to all 3 OS cell lines. Data points represent means of quadruplicate 
results from a representative experiment, repeated at least twice. Data are presented as the 











Supplementary Figure 2: TH-302 downregulates c-IAP1 and c-IAP2 in the OS BTK-143 
BTK-143 cells were seeded and treated in a similar manner to the K-HOS and NHB cells. 
Protein lysates were then collected and immunoblotted with Abs against c-IAP1, c-IAP2, 
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 Abstract: 
Tumor hypoxia is a major cause of treatment failure for a variety of malignancies. 
However, hypoxia also leads to treatment opportunities as demonstrated by the development 
of compounds that target regions of hypoxia within tumours. Evofosfamide is a hypoxia 
activated prodrug that is created by linking the hypoxia seeking 2-nitroimidazole moiety to the 
cytotoxic bromo-isophosphoramide mustard (Br-IPM). When evofosfamide is delivered to 
hypoxic regions of tumours, the DNA cross linking toxin, Br-IPM, is released leading to cell 
death. This study assessed the anticancer efficacy of evofosfamide in combination with the 
Pro Apoptotic Receptor Agonists (PARAs) dulanermin and drozitumab against human 
osteosarcoma in vitro and in an intratibial murine model of osteosarcoma. 
Under hypoxic conditions in vitro, evofosfamide cooperated with dulanermin and 
drozitumab, resulting in the potentiation of cytotoxicity to osteosarcoma cells. In contrast 
under the same conditions, primary human osteoblasts were resistant to treatment. Animals 
transplanted with osteosarcoma cells directly into their tibiae developed mixed 
osteosclerotic/osteolytic bone lesions and consequently developed lung metastases three 
weeks post cancer cell transplantation. Tumour burden in the bone was reduced by 
evofosfamide treatment alone and in combination with drozitumab and prevented 
osteosarcoma-induced bone destruction while also reducing the growth of pulmonary 
metastases. 
These results suggest that evofosfamide may be an attractive therapeutic agent, with 





Osteosarcoma (OS) is the most common primary type of cancer that develops in the 
bone and accounts for 20% of all primary osseous neoplasms (Campanacci, 1999; Pringle, 
1999). Most OS occur in young adults and children and usually develops in areas where the 
bone is rapidly growing such as the proximal tibia, distal femur and proximal humerus (Tang, 
Song, Luo, Haydon, & He, 2008). Metastatic spread of OS preferentially occurs in the lungs 
which is correlated with poor survival and is seen in 20% of patients with OS (Link et al., 
1991; Saeter et al., 1997). Over the past 20 years treatment of OS has advanced considerably 
due to the increased efficacy of conventional chemotherapeutic agents. The type, combination 
as well as the doses of chemotherapeutic agents given as well as the sensitivity of the tumour 
cells determine the patients’ response to treatment. Despite these advances in treatment, drug 
resistance still remains a problem (Chan, Grogan, Haddad, DeBoer, & Ling, 1997). In 
addition, conventional chemotherapeutic drugs have a significant impact on normal bone 
health, leading to a greater risk of developing osteoporosis and myelosuppression due to 
toxicities in the bone marrow (Gralow et al., 2009; Lustberg, Reinbolt, & Shapiro, 2012). 
The characteristics of bone lesions caused by OS are based on their radiologic 
appearance which can be either osteoblastic (osteosclerotic), osteolytic, or a combination of 
both (Mundy, 2002b). Osteolysis is common with OS and is caused by the bone resorbing 
activity of osteoclasts (Goltzman, 2001; Taube, Elomaa, Blomqvist, Beneton, & Kanis, 1994). 
Tumour growth is stimulated by factors released from the bone and in turn tumour cells 
produce factors that stimulate osteoclastic bone resorption, resulting in a mutual relationship 
of bone destruction between the cell types known as “the vicious cycle” (Chirgwin & Guise, 
2000). In contrast, osteoblastic lesions are associated with tumour cells that stimulate 
osteogenesis (Goltzman, 1997; Goltzman, Karaplis, Kremer, & Rabbani, 2000). 
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As with most solid tumours, early stage OS displays significant regions of hypoxia, 
where resistant tumour cells reside which results in tumour recurrence and metastasis, leading 
to treatment failure and poor outcomes. These hypoxic conditions found in tumor sub-regions 
are rarely observed in normal tissue, tumor hypoxia can therefore provide the basis for 
selective cancer therapy and there are a number of strategies currently being investigated to 
selectively target tumor cells in this hypoxic environment. Hypoxia-activated prodrugs 
(HAPs) selectively deliver cytostatic or cytotoxic agents to hypoxic sub regions. 
Evofosfamide (formerly TH-302) is a hypoxia-activated prodrug composed of 2-
nitroimidazole linked to bromo-isophosphoramide mustard (Br-IPM) (Jian-Xin Duan, Monica 
Banica, & W. Steve Ammons, 2007). The 2-nitroimidazole component of evofosfamide 
serves as an oxygen sensor, releasing the crosslinking DNA-alkylating Br-IPM into the 
hypoxic regions of tumors. To date, evofosfamide has been investigated both as a stand-alone 
agent and in combination with chemotherapy and other targeted cancer drugs against 
numerous solid tumor types and blood cancers (Borad et al., 2014; Chawla et al., 2014; 
Wojtkowiak et al., 2015).  
Pro-Apoptotic Receptor Agonists (PARAs), either as monotherapy or in combination 
with other agents, are generally well-tolerated by patients with very few side effects (Dine et 
al., 2016) and although phase 1/1b studies provided encouraging preliminary results, findings 
from randomized Phase 2 studies failed to demonstrate significant clinical benefit (Herbst et 
al., 2010; Kindler et al., 2012; Soria et al., 2010; Younes et al., 2010). Despite these clinical 
observations, there has been no investigation examining the anticancer efficacy of 
evofosfamide alone or in combination with either the Pro-Apoptotic Receptor Agonists 




This study investigates the cytotoxic activity of evofosfamide alone and in 
combination with dulanermin and drozitumab against human OS cells in vitro and in vivo, 
using a clinically relevant orthotopic mouse model of OS and on their subsequent lung 
metastases. 
 
Materials and Methods: 
Cells 
The human OS cell lines BTK-143 and K-HOS were obtained from ATCC (Manassas, 
VA, USA) and were authenticated by DNA (STR) profiling. Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 2mM glutamine, 100 
IU/ml penicillin, 160 g/ml gentamicin and 10% fetal bovine serum (Life Technologies, 
Carlsbad, CA, USA) in a 5% CO2-containing humidified atmosphere. The generation of 
luciferase-tagged BTK-143-TGL has been described previously (Irene Zinonos et al., 2009). 
Normal human osteoblasts (NHB) were obtained from bone marrow aspirations from 
the iliac crest of normal healthy donors or from the trabecular bone of osteoarthritic patients 
at joint replacement surgery,  grown in MEM (SIGMA, Saint Louis, Missouri, USA) 
containing L-ascorbic acid 2-phosphate (Life Technologies, Carlsbad, CA, USA) and 10% 
fetal bovine serum. Medium was then replaced at 4 day intervals cells were then consequently 
sub cultured by treatment with a (0.1%) (w/v) mixture of collagenase and dispase. In all 
experiments, cells from the first passage were used in all experiments. 
Drugs 
Threshold Pharmaceuticals (South San Francisco, CA, USA) provided the 
evofosfamide powder which was dissolved in a sterile saline solution at a concentration of 
13.2mM. The Caspase Inhibitor-1 ZVAD-fmk, was purchased from Calbiochem Inc. (La 
Jolla, CA, USA). 
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Both drozitumab and dulanermin were a gift from Dr Avi Ashkenazi, Genentech, Inc. 
(South San Francisco, CA, USA). Affinity Pure Goat anti-human IgG Fcγ fragment was 
purchased from Jackson Immuno Research Laboratories Inc. (West Grove, PA, USA). 
Cell Viability Assay 
To determine the cytotoxicity of evofosfamide on cell growth, 1 x 10
4
 cells per well 
were seeded in 96-well microtitre plates and allowed to attach overnight. Cells were then 
treated with increasing concentrations of evofosfamide (1-100M) alone and in combination 
with 100ng/ml of either dulanermin or drozitumab for 24 hours under both hypoxic (1% O₂) 
and normoxic conditions. Drozitumab was cross-linked with an anti-human IgG Fcγ for 30 
minutes at 4˚C prior to treatment before all in vitro experiments. Crystal Violet staining was 
used to determine cell viability and optical density was measured at 570 nm wavelength 
(OD570). Results of representative experiments are presented as the mean +/- SD which were 
performed in triplicate and repeated at least 3 times. 
Apoptosis Analysis 
Measurement of DEVD-caspase activity with and without Caspase Inhibitor 1, ZVAD-fmk 
DEVD-caspase activity was assayed by cleavage of the fluorogenic substrate zDEVD-
AFC and based on the peptide sequence at the caspase-3 cleavage site of poly (ADP-ribose) 
polymerase. Cells were grown in 96 well plates at a density of 1x10
4
/well and treated for 24 
hours as indicated, washed once with PBS, and resuspended in 30μl lysis buffer containing 
5mmol/L EDTA, 5mmol/L Tris-HCl and 10% Igepal (pH 7.5). Cell lysate containing 20μg of 
protein was added to each well containing 8μmol/L substrate in 1ml fluorometric protease 
buffer which contained 10% sucrose, 50mmol/L HEPES, 0.1% CHAPS (pH 7.4), 10mmol/L 
DTT. 
Fluorescence was then quantified (Ex 400 and Em 505) after 4 hours at room 
temperature using a BMG FLUOstar OPTIMA microplate reader. 
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Results were expressed relative to the protein concentration of the sample, which was 
determined using a commercial BCA protein assay reagent from Thermo Fisher Scientific 
(Waltham, MA, USA). Caspase Inhibitor 1, ZVAD-fmk, was resuspended at a concentration 
of 50mM and added to the cells at 50μM alone, with evofosfamide at 50μM, drozitumab + 
anti-human IgG Fcγ or dulanermin at 100ng/ml. 
Western Blot analysis 
Cells were treated with 50M of evofosfamide, alone or in combination with 
100ng/ml of either dulanermin or drozitumab (cross-linked with an anti-human IgG Fcγ), 
under hypoxic (1% O2) and normoxic (21%O2) conditions for 24 hours and lysed in buffer 
containing 150mM NaCl, 10mM Tris HCl (pH 7.6), 0.1% sodium dodecyl sulphate, 1% 
Triton X-100, 2mM sodium vanadate and a protease inhibitor tablet (Roche Diagnostics, 
Mannheim, Germany). Protein lysates were heated for 10 minutes at 70
o
C and loaded under 
reducing conditions into 4-12% polyacrylamide gels for electrophoresis. Separated proteins 
were transferred to PVDF membranes (GE Healthcare, Buckinghamshire, UK) 
electrophoretically and blocked in PBS containing 5% blocking reagent (GE Healthcare, 
Buckinghamshire, UK) and 0.1% Tween 20 for 1 hour at room temperature. 
Immunodetection was performed at 4
o
C overnight in blocking reagent/PBS, using the 
following primary antibodies mAb anti-caspase-8, pAb anti-caspase-9, mAb anti-caspase-3 
and pAb anti-bid which were purchased from Cell Signaling Technology (Beverly, MA, 
USA), pAb anti-Inhibitor of Apoptosis 2 (cIAP2), pAb anti-Inhibitor of Apoptosis 1 (cIAP1), 
pAb anti-XIAP, pAb death receptor 4 (DR4), pAb death receptor 5 (DR5), pAb decoy 
receptor 1 (dcR1) and pAb decoy receptor 2 (dcR2) purchased from R&D systems, pAb anti-
Poly-(ADP-Ribose) Polymerase (PARP) from Roche Diagnostics (Mannheim, Germany). 
Anti-actin mAb was used as a loading control and was purchased from SIGMA, Saint Louis, 
Missouri, USA. 
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All primary antibodies were used at the dilutions suggested by their manufacturers. 
Membranes were then rinsed three times with PBS containing 0.1% Tween-20 and incubated 
for 1 hour with a 1:5,000 dilution of anti-goat, anti-mouse, or anti-rabbit alkaline 
phosphatase-conjugated secondary antibodies (Thermo Fisher Scientific, Waltham, MA, 
USA). The ECF substrate reagent kit purchased from (GE Healthcare, Buckinghamshire, UK) 
and the FluorImager (Molecular Dynamics Inc., Sunnyvale, CA, USA) were used to visually 
assess and quantify the protein bands. 
Animals 
For a minimum period of 1 week prior to the commencement of experimentation, 4 
week old female athymic mice were acclimatized to the animal housing facility under 
pathogen free conditions (Institute of Medical and Veterinary Services Division, Gilles Plains, 
SA, Australia). Throughout the experiments the general physical well-being and weight of 
animals were monitored. All experimental procedures on animals were carried out with strict 
adherence to the guidelines and rules for the ethical use of animals in research and were 
approved by the Animal Ethics Committees of the Institute of Medical and Veterinary 
Science and the University of Adelaide, SA, Australia. 
Intra-tibial injections of osteosarcoma cells 
The BTK-143-TGL OS cell line was cultured as described previously until 70-80% 
confluency was reached. Cells were removed from flasks with 2mM EDTA and resuspended 
at 1x10
5 
cells per 10μl PBS and kept on ice in an eppendorf tube. The left tibia was wiped 
with 70% ethanol and with the knee flexed, coupled to a Hamilton syringe a 27 gauge needle 
was inserted through the tibial plateau and 1x10
5
 BTK-143-TGL cells resuspended in 10l of 
PBS were injected in the marrow space. As the control all animals were injected with PBS 
into the contralateral tibia. Mice were randomly assigned into groups of 7 animals and 7 days 
after cancer cell transplantation drug dosing started. 
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Evofosfamide was administered via i.p injection once a day for 5 days followed by 2 
days of rest at 50mg/kg body weight, whereas drozitumab was administered at 3mg/kg i.p 
once a week until the end of the experiment. 
In vivo bioluminescent imaging 
The IVIS 100 Imaging system (Xenogen, Alameda, CA) was used weekly to perform 
non-invasive, whole body imaging to monitor the luciferase-expressing OS cell line BTK-
143-TGL in mice using 100 μl of the D-Luciferin (Xenogen Alameda, CA) solution at final 
dose of 3mg/20g mouse body weight was injected i.p. Mice were then gas-anaesthetized with 
Isoflurane (Faulding Pharmaceuticals, Salisbury, SA, Australia). Images were acquired from 
the side angle for 0.5-30 seconds (representative images are shown at 1 second) and the 
Xenogen Living image (Igor Pro version 2.5) software was used to capture and quantify 
photon emission from mice in photons/sec/cm
2
. 
Micro-computed tomography ex vivo analysis 
The SkyScan-1072 high-resolution μCT Scanner (Kontich, Skyscan, Belgium) was 
operated at 80kV, 120 μA, rotation step 0.675, with a 0.5 mm Al filter and scan resolution of 
5.2μm/pixel was used to scan surgically resected limbs. Cross sections of the samples were 
reconstructed using a cone-beam algorithm (software Cone rec, Skyscan). The growth plate 
was identified using the 2D images obtained from the μCT scan and starting from the growth 
plate/tibial interface and moving down the tibia 450 sections were selected for quantification.  
To determine 3D bone morphometric parameters (software CTAn, Skyscan), 3D 
evaluation was performed on all data sets acquired by selecting total bone of the proximal 
tibia, the cross sections were reconstructed using a cone-beam algorithm (software Cone_rec, 
Skyscan). Files were then imported into CTAn software (Skyscan) for 3D analysis and 3D 
image generation. All images are viewed and edited using ANT visualisation software 
(Skyscan). 
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Data Statistics and Analysis 
Experiments were performed in triplicate and data presented as mean ± SE. SigmaStat 
for Windows version 3.0 (Systat Software, Inc., Port Richmond, CA) was used for all 
statistical analysis using the unpaired Students’ T test. Spearman Rank correlation coefficient 
was used to assess the association between two variables and comparisons between groups 





Evofosfamide cooperates with drozitumab and dulanermin, displaying increased hypoxia-
selective cytotoxicity against OS cells. 
Human OS cell lines K-HOS and BTK-143were assessed for their sensitivity to the 
cytotoxic activity of evofosfamide alone and in combination with a maximum dose of 
100ng/ml of drozitumab or dulanermin for 24 hours under normoxic (21% O₂) and hypoxic 
(1% O₂) conditions. In both OS cell lines as a single agent, evofosfamide had minimal toxicity 
under normoxic conditions. In contrast, under hypoxic conditions, evofosfamide dose 
dependently decreased cell viability in both OS cell lines, with 43% viability for the BTK-143 
cells and 65% viability for the K-HOS cells at 25μM. Under normoxic conditions, both OS 
cell lines were resistant to the cytotoxic activity of drozitumab and dulanermin alone at 
100ng/ml. However under hypoxic conditions, K-HOS cells were comparably more sensitive 
to the cytotoxic activity of both drozitumab and dulanermin alone (39 and 47% viability 
respectively), whereas BTK-143 cells were relatively resistant (94 and 77% viability). 
Both OS cell lines showed a significant increase in cytotoxicity when either 
drozitumab or dulanermin were combined with evofosfamide in a dose dependent manner 
under hypoxic conditions, resulting in 95% loss of viability at 25μM for both OS cell lines 
(Fig. 1A). In contrast, primary normal human osteoblasts, cultured from patients undergoing 
hip replacement surgery, were resistant to the cytotoxic activity of evofosfamide at 100μM in 












Figure 1: Activity of evofosfamide in combination with drozitumab and dulanermin against 
OS cells and primary normal human osteoblasts in vitro. (A) OS cell lines BTK-143 and K-
HOS were seeded in 96 well plates at 1x10
4
 cells per well and treated with increasing doses of 
evofosfamide alone and in combination with either drozitumab or dulanermin under normoxic 
(21% O2) and hypoxic (1% O2) conditions for 24 hours. (B) Primary normal human 
osteoblasts were resistant to evofosfamide and the combination with either drozitumab or 
dulanermin under the same conditions. Cell viability was assessed by crystal violet staining. 
Data points show means of quadruplicate results from a representative experiment, repeated at 
least twice and presented as the mean SD of quadruplicate wells and expressed as a 
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Evofosfamide mediated OS cytotoxicity is only partly caspase 3 dependant. 
The increase in caspase-3 activation with 50μM of evofosfamide treatment under 
hypoxic conditions alone and in combination with drozitumab or dulanermin (100ng/ml) was 
associated with a decrease in cell viability. However co-administration with ZVAD-fmk, a 
pan-caspase inhibitor did not prevent the reduction in cell viability caused by evofosfamide in 
both OS cell lines under hypoxic conditions, despite irreversibly inhibiting the activity of 
caspase-3 (Fig. 2), suggesting that the mechanisms involved in evofosfamide-mediated 
cytotoxicity are not entirely caspase dependent. 
However ZVAD-fmk completely reversed the cytotoxic activity of both drozitumab 
and dulanermin in both OS cell lines, indicating that the cytotoxicity of these PARAs against 
these OS cells is largely caspase dependant, this being in line with the well-established 
mechanism of action of these pro-apoptotic agents. When either drozitumab or dulanermin 
was combined with evofosfamide and the caspase inhibitor ZVAD-fmk was added, there was 
a significant reduction in cytotoxicity against both OS cell lines when compared to the 
combination of these drugs without ZVAD-fmk. 
The molecular determinants involved in evofosfamide-mediated apoptotic signaling 
alone and in combination with drozitumab or dulanermin were characterised (Fig. 3). 
Evofosfamide alone treatment at 50μM under hypoxic conditions (1% O₂), for 24 hours 
activated the caspase cascade with robust cleavage of the initiator caspase-8, caspase-9, 
caspase-3 and cleavage of poly ADP-ribose polymerase (PARP). The mitochondrial pro-
apoptotic Bcl-2 family protein BID, inhibitor of apoptosis proteins cIAP1, cIAP2 and XIAP 




The combination of evofosfamide with dulanermin or drozitumab in both OS cell lines 
resulted in increased processing of caspases 8, 9, 3 and PARP. Importantly, combination 
treatment under hypoxia resulted in the robust cleavage of BID, likely resulting in the 
amplification of apoptotic signaling. 
Interestingly we observed a significant decrease in the levels of inhibitor of apoptosis 
proteins cIAP1, cIAP2 and XIAP in the K-HOS cell line. The levels of cIAP2 in the BTK-143 
remained unchanged. 
Under hypoxic conditions evofosfamide alone and in combination with either 
dulanermin or drozitumab up-regulated the death receptor DR5 in both cell lines. In the K-
HOS cell line which was more sensitive to dulanermin and drozitumab when compared to the 
BTK-143 cell line, dulanermin and drozitumab alone also upregulated DR5 as single agents 
under both normoxic and hypoxic conditions. There were no significant differences in the 






















Figure 2: The cytotoxic activity of dulanermin and drozitumab is caspase dependant, 
whereas evofosfamide is not. OS cell lines were seeded in 96 well plates at 1x10
4
 cells per 
well and treated with evofosfamide alone at 50M and with drozitumab IgG 100ng/ml, 
dulanermin 100ng/ml or co-incubated with the broad specificity caspase inhibitor z-VAD-fmk 
(50M). To exclude possible toxic effects of the inhibitor, cells were also treated with the 
inhibitor alone under normoxic and hypoxic (1% O2) conditions. Cell lysates were used to 
determine caspase-3-like activity, using the caspase-3 specific fluorogenic substrate, zDEVD-
AFC and cell viability was assessed via crystal violet staining. Data points show means of 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Apoptotic signalling of evofosfamide, dulanermin and drozitumab against OS 
cells. OS cells were seeded at 2 x 106 per T25 flask and were treated with evofosfamide at 
50μM, dulanermin and drozitumab at 100ng/ml under normoxic (21% O2) and hypoxic (1% 
O2) conditions. After 24 hours cells were lysed and protein was collected. Cell lysates were 
analysed by polyacrylamide gel electrophoresis and transferred to PVDF membranes for 
Immunodetection as described in the Materials and Methods and immunoblotted with various 

































































































































































































































































































































Cytotoxic activity of evofosfamide and drozitumab against osteosarcoma-induced bone 
destruction 
Drozitumab was specifically chosen as opposed to dulanermin in this preclinical 
study due to its ability to specifically bind to DR5 and not the TRAIL decoy receptors. In 
addition, drozitumab has a longer half-life when compared to dulanermin (Ashkenazi, 
Holland, & Eckhardt, 2008). 
To investigate the anticancer efficacy of drozitumab and evofosfamide against 
osteosarcoma progression and metastasis, an orthotopic model of OS  was used in which 
luciferase tagged BTK-143-TGL cells were directly transplanted into the tibial marrow cavity 
of female athymic nude mice and accurately monitored and quantified using non-invasive 
bioluminescence imaging over a 28 day period (I. Zinonos et al., 2009). Treatment with 
drozitumab, evofosfamide or the combination of both agents commenced 7 days after the 
intratibial OS cell injections. All vehicle treated animals showed an increase in mean photon 
emission exponentially, which indicated an increase in tumor burden palpable from day 7 
onwards, reaching a maximum signal at day 28, at which point animals were humanely killed. 
In contrast, treatment with evofosfamide or drozitumab showed a reduction in tumor burden 
over the same period in all animals. Importantly, the combination demonstrated a far greater 
anticancer efficacy in the bone (Fig 4A and B). The tibiae of all mice were dissected at the 
end of the experiment and the qualitative and quantitative assessment of bone destruction was 
analysed using high resolution µCT (Fig 4C). In the vehicle treated animals extensive 
osteolysis was clearly evident such that the net loss in bone volume (BV) was 69% in the left 
tumor-bearing tibiae when compared to the contralateral non-tumor bearing right tibiae. 
Although tumor burden was reduced by evofosfamide treatment, this did not prevent 
bone destruction such that the extent of osteolysis was not significantly different when 
compared to the vehicle treated group. 
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Remarkably, treatment with drozitumab alone resulted in extensive bone remodeling, 
resulting in a gain of bone volume of 27% when compared to the untreated right tibia. Micro-
CT analysis showed extensive bone remodeling that was noticeable under the growth plate 
and extended down the length of the tibia where the tumor resided. Tumour healing in the 
treatment of osteosarcoma in patients if often correlated with a significant increase in 
calcification, which would account for the increase in calcification in the tumour affected tibia 
of mice treated with drozitumab (S. Ferrari, Balladelli, Palmerini, & Vanel, 2013). In animals 
treated with the combination of drozitumab and evofosfamide, the tibia had a normal 
appearance due to the full mineralization of the cortical bone, demonstrating additional 
protection of the bone architecture, less calcification and more advanced bone remodeling, 
such that the net gain of BV was reduced to 6%. 
Ex-vivo bioluminescence imaging showed no differences between the treated groups 
(3 out of 7 mice) in the number of mice that developed lung metastases. However the tumor 
burden in the lungs of the mice with metastases which was measured as a function of 
bioluminescence signal showed a reduction in tumour growth with evofosfamide treatment. In 
addition, drozitumab maintained its cytotoxicity against metastatic OS cells in the lungs, 










Figure 4: Drozitumab co-operates with evofosfamide to reduce OS intratibial tumours in 
vivo. BTK-143-TGL cells were injected directly into the tibial marrow cavity of 4 week 
female athymic mice, allowed to establish for 7 days, as described in the methods, mice were 
imaged weekly using the Xenogen IVIS 100 bioluminescence imaging system. (A). 
Representative whole body bioluminescent images of a single mouse from each group during 
the course of the experiment are shown. (B). The line graph, showing average tumor signal 
over time, expressed as mean photon counts per second during the course of the experiments 
are shown. Animals receiving treatment with evofosfamide and drozitumab as single agents 
showed a significant delay in tumor growth. In addition, all mice receiving the combination 
of evofosfamide and drozitumab showed a further delay of tumor growth when compared 
with each agent individually. (C). Quantitative assessment of Total bone loss (%) comparing 
the tumor bearing tibiae of each group to the contralateral tibiae and the qualitative 3-D 
micro CT images show the osteolytic nature of the BTK-143-TGL cell line, which was 
reduced by drozitumab alone and the combination of evofosfamide and drozitumab. (D). 
Average lung tumor growth was assessed via bioluminescence showing evofosfamide, 
drozitumab and the combination of both agents caused a reduction in lung tumor growth of 
the BTK-143-TGL cell line when compared to the vehicle group. Data shown in each case 
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Effect of evofosfamide on bone metabolism 
Our experimental approach also provides an opportunity to assess the normal bone 
parameters after treating the mice with evofosfamide, drozitumab and the combination of 
both. After three weeks of treatment, the use of high resolution micro-CT analysis to compare 
the contralateral non tumor bearing tibiae of treated and untreated animals showed no 
differences in any of the micro architectural bone morphometric parameters, which included 

















Table 1:  Comparison of bone morphometric parameters of contralateral non tumour 








  Mean SE Mean SE Mean SE Mean SE 
Bone Volume(mm3) 2.34 0.05 2.27 0.07 2.31 0.14 2.30 0.11 
Bone Surface (mm2) 191.68 4.07 194.55 4.94 188.71 6.58 195.52 10.91 
Inter-section Surface. (mm2) 0.36 0.03 0.32 0.04 0.38 0.03 0.36 0.09 
Trabecular Space (mm) 1.53 0.02 1.49 0.04 1.57 0.04 1.45 0.03 
Trabecular Number (1/mm) 0.16 0.07 0.18 0.01 0.16 0.02 0.20 0.02 
Trabecular Thickness (mm) 0.05 0 0.05 0 0.06 0 0.05 0 
Trabecular Pattern factor (1/mm) 24.24 1.37 21.17 1.79 23.90 0.77 22.05 1.05 
Structure Model Index 2.14 0.04 2.04 0.23 2.08 0.03 1.92 0.06 
Bone volume, bone surface, inter-section surface, trabecular space, trabecular number, 
trabecular thickness, trabecular pattern factor and structure model index were measured by 
three dimensional analysis of  μCT images of the contralateral tibial bone. Results are 
expressed as mean ± SE. Significance of results is with respect to untreated animals obtained 





In addition to surgical intervention, chemotherapeutic agents such as doxorubicin, 
etoposide, cisplatin and cyclophosphamide used alone, or in combination have significantly 
improved overall survival for patients with OS. Yet despite these improvements in treating the 
primary tumour, a large number of patients with OS eventually develop lung metastases, even 
after surgical excision and conventional chemotherapy. There is a need to therefore, develop 
safe and new approaches for OS treatment (Botter, Neri, & Fuchs, 2014; Jin-Peng He & Jin 
Guo, 2014; Yang & Zhang, 2013). 
It must be noted that when compared to other tissues, the bone marrow and in particular 
the haemopoietic niche close to the endosteal surface is hypoxic, which is required for normal 
haemopoiesis to occur (Miharada et al., 2011). Unlike soft tissue tumors, OS can also adapt to 
this hypoxic bone microenvironment. The ability to target OS in this hypoxic bone 
environment is therefore an important feature that evofosfamide has over other cancer 
therapies. In addition conventional chemotherapeutics are usually cytotoxic to normal bone 
cells in the bone marrow, an important goal of anticancer treatment is to selectively target 
cancer cells but not normal bone cells.  
A combinatorial approach using agents with additive or synergistic cytotoxic activities 
are appealing because they allow lower drug doses to be used, which reduce harmful side-
effects, particularly in the bone. Consistent with our previous published data (V. Liapis et al., 
2015; V. Liapis et al., 2016) under normoxic conditions evofosfamide alone resulted in 
minimal toxicity against OS, whereas under hypoxic conditions evofosfamide decreased OS 
cell viability. This cytotoxic activity was further increased when evofosfamide was combined 
with either drozitumab or dulanermin under hypoxic conditions. 
 
83 
The combination of the chemotherapeutic agents’ drozitumab and dulanermin with 
evofosfamide was not toxic to either normal human bone cells in vitro or normal bone 
metabolism in vivo, corroborating with previous studies which demonstrate that these agents 
individually are nontoxic to normal bone. (Agatha Labrinidis et al., 2009; V. Liapis et al., 
2015; I. Zinonos et al., 2009). These results highlight not only the hypoxic selectivity of 
evofosfamide, but also the specific tumor selectivity of both evofosfamide and PARAs. 
In the search for more effective treatments for OS, PARAs including recombinant 
dulanermin and the agonistic antibody drozitumab induce apoptosis through different but 
overlapping signaling pathways, whereas evofosfamide induces apoptosis mainly through 
caspase-independent mechanisms as described previously (Vasilios Liapis et al., 2016). As a 
result, the combination of PARAs and evofosfamide were considerably more cytotoxic to 
tumour cells that resist cytotoxic activity through a single pathway, where inhibiting caspase 
activity to prevent the activity of both drozitumab and dulanermin still resulted in both OS cell 
lines under hypoxic conditions being sensitive to the cytotoxic activity of evofosfamide. This 
is also reflected by the activation of caspase-8, caspase-9, caspase-3, PARP, cleavage of Bid, 
a member of the Bcl-2 family protein, and the downregulation of c-IAP1 when evofosfamide 
was combined with dulanermin or drozitumab as well as both PARAs activating the extrinsic 
pathway by the upregulation of DR5. 
Based on our in vitro results, the therapeutic potential of evofosfamide was expected to 
be greatest in combination with adjuvant cytotoxic chemotherapy. When transplanted into the 
tibial marrow cavity of mice, BTK-143 cells are highly osteolytic and this results in extensive 
bone destruction and the development of metastases to the lung three to four weeks post 
cancer cell transplantation. 
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This in vivo model mimics OS activity in the bone as seen in patients with the disease 
and is ideal for determining the potential of drug treatment on cancer growth in the bone as 
well as cancer-induced bone destruction (Vasilios Liapis et al., 2015; I. Zinonos et al., 2009). 
The activity of evofosfamide in combination with drozitumab was tested in this context, in a 
preclinical model of OS progression and development for the following reasons. In contrast to 
dulanermin, which has a short bioavailability of 30 minutes, which requires daily treatment 
for patients and the inability to bind to death-inducing TRAIL receptors in various cancer 
types, preferring to bind with the decoy TRAIL receptors (Amarante-Mendes & Griffith, 
2015; Ashkenazi et al., 1999), drozitumab is a fully agonistic human monoclonal antibody that 
specifically binds to and activates DR5 in the same manner as dulanermin (I. Zinonos et al., 
2009). Drozitumab has a half-life ranging from several days to weeks and has been developed 
to specifically target DR5 (Ashkenazi, 2008a) and not the TRAIL decoy receptors. In 
addition, circulating Fragment Crystalline Gamma (Fcγ) receptors expressed on the surface of 
various immune cells (Holland, 2013; Robak, 2013), crosslink with drozitumab which leads to 
enhanced antibody-dependent, cell-mediated cytotoxicity (ADCC) (Wilson et al., 2011), 
resulting in immune cell activation leading to recruitment of other Fcγ receptor expressing 
cells to the tumor microenvironment (Amarante-Mendes & Griffith, 2015; Wilson et al., 
2011). The apoptotic tumor cells are then phagocytosed by the activated Fcγ receptor 
expressing immune cells (Takeda et al., 2004), further enhancing the cytotoxic activity of 
drozitumab against cancer. 
The activity of drozitumab against OS in bone has yet to be reported and in addition, 
this OS cell line is relatively resistant to drozitumab in vitro, allowing the detection of any 
synergistic or additive activity to be easily observed. As a single agent evofosfamide had 
limited impact in reducing tumour growth in the tibia or protecting the tibia from the cancer 
induced bone destruction caused by this highly aggressive osteolytic cell line. 
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The cytotoxic activity displayed by drozitumab in vivo contradicts the resistance of this 
human osteosarcoma shown in vitro. A possible explanation to account for the increase in 
cytotoxicity of drozitumab in vivo is the circulation of Fcγ receptors expressed by leukocytes 
in mice. The engagement of leukocyte Fcγ receptors by antibody-antigen complexes leads to 
an enhanced antibody-dependent, cell-mediated cytotoxicity (ADCC) (Wilson et al., 2011), 
which can interact more efficiently with the DR5 agonistic antibody drozitumab when 
compared to artificial Fc crosslinking in vitro, leading to improved cytotoxicity against the 
human osteosarcoma in the tibia and lungs of the mice. 
The combination of both evofosfamide and drozitumab had a profound effect in 
preventing growth of the tumor within the tibia which also translated to increased bone 
protection and a reduction in tumour burden in the lung. This may be related to the ability of 
evofosfamide to upregulate DR5 expression under hypoxic conditions, resulting in increased 
sensitivity to Drozitumab as observed in previous studies (Alexiou, Tsamis, & Kyritsis, 2015). 
In addition, each drug specifically targets tumours regions of different oxygen tensions 
accordingly.  
PARAs including drozitumab and dulanermin have been tested either alone or in 
combination with other agents in phase I and II clinical trials (Dine et al., 2016), with little 
clinical benefit observed to date which has led to the discontinuation of the development of 
PARAs in many cases (Holland, 2014). However, none of these clinical trials have examined 
the anticancer efficacy of PARAs against cancers in the bone such as OS. 
Evofosfamide is currently being evaluated both as monotherapy and in combination 
with conventional chemotherapy and radiotherapy in numerous phase I and phase II clinical 
trials against a variety of cancer types. 
86 
To date, two phase 3 trials targeting unresectable or metastatic soft tissue sarcoma 
NCT01440088 and unresectable pancreatic adenocarcinoma NCT01746979 (Alama, Orengo, 
Ferrini, & Gangemi, 2012) failed to meet their primary endpoint of improving overall survival 
with statistical significance. Nonetheless, from the observations in phase I and II clinical trials 
of evofosfamide and PARAs, and from the results presented in this study, which indicate that 
these compounds are nontoxic to normal bone metabolism suggest that OS patients may 
benefit from evofosfamide when used in combination with PARAs. 
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Tumor hypoxia is a major cause of treatment failure and poor outcome for a wide 
variety of malignancies. Within most solid tumours, there are significant areas of hypoxia, 
which contain cancer cells that resist conventional chemotherapy and radiotherapy, 
predisposing to tumor recurrence and metastasis. However, tumor hypoxia also provides 
treatment opportunities, exemplified by the development of highly active compounds known 
as HAPs that can specifically target tumor hypoxic zones. 
In considering the use of the HAP evofosfamide specifically for cancers in the bone, it 
is important to note that the bone marrow, particularly the hematopoietic niche proximal to the 
endosteal surface, is hypoxic and this is a prerequisite for normal haemopoiesis. In humans, 
the average oxygen tension (pO2) in the bone marrow is between 1 and 7% (cf atmospheric 
oxygen = 21%) (Carreau, El Hafny-Rahbi, Matejuk, Grillon, & Kieda, 2011). Cancer cells 
normally home to hypoxic endosteal niches where the oxygen tension is estimated to be 
<1.3% (Spencer et al., 2014). Unlike soft tissue tumours, cancer cells in bone are adapted to 
survive and grow in a microenvironment, which is already hypoxic (Brahimi-Horn, Chiche, & 
Pouyssegur, 2007). Therefore tumor hypoxia is a major contributor to the incurability of bone 
cancer. 
The results of the first aim which investigated the anticancer activity of evofosfamide 
against osteosarcoma showed that in vivo evofosfamide dose-dependently was cytotoxic to 
human OS cells selectively under hypoxic conditions, whereas primary normal human 
osteoblasts under the same conditions were relatively resistant to treatment, highlighting not 
only the hypoxic selectivity but also the tumor selectivity of the drug, which is likely related 
to the more rapid proliferation of tumor cells when compared to normal cells. In vivo 
evofosfamide as a single agent delayed tumor growth in bone and cooperated with 
doxorubicin for increased anticancer efficacy. 
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This effect was associated with significant protection from OS induced bone 
destruction and was observed in two distinct intratibial mouse models of human OS giving 
rise to different types of bone lesions. Evofosfamide alone reduced the incidence of lung 
metastases in both OS models. However, the tumor burden within the lungs of the remaining 
animals with metastases was no different from those seen in the vehicle treated groups, 
suggesting that osteosarcoma cells that escaped from the bone marrow and lodged into the 
lungs were refractory to evofosfamide treatment in this highly oxygenated environment, 
highlighting the hypoxia selectivity of this drug in vivo. In contrast, doxorubicin maintained 
its tumor suppressive activity in the lung. 
To date, the activity of evofosfamide against breast cancer both at the orthotopic site 
and bone metastases has not been reported. Therefore the second aim investigated the 
anticancer efficacy of evofosfamide in a preclinical model of breast cancer. In vitro 
evofosfamide exhibited relatively minimal toxicity under normoxic conditions, against a panel 
of human breast cancer lines, whereas under increasing hypoxia evofosfamide treatment dose 
dependently decreased the cell viability of a variety of human breast cancer cell lines. Normal 
breast epithelial cell lines MCF-10A and MCF-12A were also equally sensitive to 
evofosfamide under hypoxic conditions, which may be related to their proliferative capacity 
being similar to that of breast cancer cells. In contrast, primary dermal and normal mammary 
fibroblasts were relatively resistant to the cytotoxic activity of evofosfamide under the same 
conditions. 
The anticancer efficacy of evofosfamide alone and in combination with paclitaxel 
against breast cancer growing in the orthotopic site and in the bone marrow was assessed by 
using the aggressive and highly osteolytic human MDA-MB-231-TXSA breast cancer cell 
line in vivo. 
 
90 
When these human breast cancer cells were injected into the mammary fat pad of 
mice, treatment with evofosfamide or paclitaxel as single agents showed a significant 
reduction in tumor burden over the same period, whereas the combination of both was more 
effective in reducing tumor growth. In the intratibial model, evofosfamide treatment inhibited 
tumor growth in bone, leading to a significant reduction in the overall tumor burden. 
However, the reduction in tumor burden did not translate to a significant inhibition of 
osteolysis attesting to the aggressive osteolytic properties of these cells. In contrast, paclitaxel 
as a single agent was highly effective in reducing tumor load in bone while also protecting the 
bone from cancer induced bone destruction. The combined treatment resulted in a further 
reduction in tumor burden. 
The third aim investigated evofosfamide in combination with the PARAs drozitumab 
and dulanermin. To date, there has been no assessment of PARAs for the treatment of 
osteosarcoma. PARAs have been investigated previously against breast cancer growth in bone 
and were shown to inhibit intra and extra osseous bone growth while being non-toxic towards 
normal bone metabolism (I. Zinonos et al., 2009). Consistent with the results of the first aim, 
evofosfamide alone exhibited relatively minimal toxicity under normoxic conditions, whereas 
under hypoxia evofosfamide decreased OS cell viability. This cytotoxic activity was further 
increased when evofosfamide was combined with either drozitumab or dulanermin under 
hypoxic conditions. In contrast, normal human osteoblasts were resistant to the cytotoxic 
activity of evofosfamide alone and in combination with either drozitumab or dulanermin 
under the same conditions. 
As single agents in vivo, evofosfamide and in particular drozitumab were highly 
effective in reducing primary tumor burden and metastatic burden in the lungs. Evofosfamide 
however did not significantly reduce the cancer induced bone destruction caused by this 
highly aggressive osteolytic osteosarcoma cell line. 
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However the combination of both agents further prevented growth of the tumor within 
the tibia which also translated to increased bone protection and a reduction in tumour burden 
in the lung. PARAs including drozitumab and dulanermin, have been tested alone or in 
combination with other agents in phase I and II clinical trials and little clinical benefit has 
been observed to date which has led to the discontinuation of the development of PARAs in 
many cases (Holland, 2014). However, none of these clinical trials have examined the 
anticancer efficacy of PARAs against cancers in the bone such as OS.  
To date no data exist on the effects of evofosfamide or any other HAP for that matter on 
normal bone metabolism in the context of osteoclasts, osteoblasts, or osteocyte survival and 
function. From these three studies, the micro architectural bone morphometric parameters of 
the contralateral non tumor injected tibiae from untreated and evofosfamide treated animals 
were compared using high resolution micro-CT which demonstrated no changes in micro 
architectural bone parameters including, total or trabecular BV measurements with 
evofosfamide treatment. 
The results obtained in addressing the aims of this thesis as well as results obtained 
from the early stages of clinical trials of evofosfamide for the treatment of other cancer types, 
including the lack of toxicity to normal bone cells, suggest that patients diagnosed with 
primary OS may benefit from evofosfamide therapy when used in combination with the 
conventional chemotherapeutic drug doxorubicin. These studies also indicate that patients 
may also benefit from evofosfamide when used in combination with PARAs as both these 
compounds are nontoxic to normal bone metabolism when compared to chemotherapeutic 
treatment of patients suffering from OS. 
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Data generated the second aim which investigated the anticancer efficacy of 
evofosfamide against breast cancer further supports the clinical development of evofosfamide 
as a novel approach in the treatment of patients with breast cancer, especially those with 
existing bone metastases. 
The data presented in this thesis provides an important preclinical evaluation for the 
treatment of cancer that originates in the bone such as osteosarcoma or metastasizes to the 
bone such as breast cancer using the HAP evofosfamide with either conventional 
chemotherapeutic drugs such as doxorubicin and paclitaxel, or drugs such as the PARAs 
drozitumab and dulanermin which, although the PARAs drozitumab and dulanermin have 
failed to progress further than phase II clinical trials, they are continually investigated by 
researchers and clinicians because they are well tolerated by patients with only small side 
effects. 
While outcomes for the treatment of patients suffering from bone cancers have 
improved over the past 30 years with the use of aggressive chemotherapeutics, these 
chemotherapeutic drugs cause many side effects and often give rise to second malignancies. In 
addition, the frequent acquisition of drug resistance as well as the toxic side effects which is 
often associated with the use of these drugs is a serious problem. Therefore evofosfamide and 
PARAs may have potential roles in the treatment of bone cancer, given that data generated in 
this thesis and form previous preclinical studies suggest that both evofosfamide and PARAs 

























Tumour hypoxia has been pursued as a potential selective cancer drug treatment for 
over 30 years. Yet despite the link between hypoxia with treatment resistance and poor 
prognosis, a number of HAPs including evofosfamide have failed to demonstrate efficacy in 
phase III clinical trials and as yet no HAPs have been FDA approved. 
Evofosfamide, which was the most advanced and the least toxic of all HAPs that 
have entered clinical trials, failed two phase III trials for the treatment of advanced pancreatic 
cancer (MAESTRO) and advanced soft tissue sarcoma (TH-CR-406/SARC021). The reason 
for the failure of the MAESTRO study was that evofosfamide did not improve overall survival 
in combination with gemcitabine when compared to gemcitabine plus placebo. 
Pancreatic ductal adenocarcinoma is incurable and the most lethal common cancer 
because it is usually diagnosed at an advanced stage which is resistant to therapy (Ryan, 
Hong, & Bardeesy, 2014). Although the primary endpoint of overall survival in the 
MAESTRO study narrowly missed statistical significance (p=0.0589, where p=0.05 is 
statistically significant), secondary endpoints, overall response rates and progression free 
survival gave significant improvements for patients treated with gemcitabine plus 
evofosfamide compared to gemcitabine plus placebo (Russo & Saif, 2016). In addition a 
subgroup of 123 patients enrolled in the treatment arm at Japanese and South Korean sites had 
a risk of death reduction of 42% when compared to the control arm (Zeng, 2016). These 
results, which include the narrowly missed statistical significance of p=0.058, require further 
analysis to determine whether the phase III failure is due to the trial design or the drug 
evofosfamide itself, leading to the possibility that there may still be an opportunity to treat 
patients with pancreatic cancer with evofosfamide. 
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Importantly, in the context of cancer in the bone updated data from the phase II study 
investigating evofosfamide in combination with bortezomib and low dose dexamethasone 
(NCT01522872) suggests that of the 18 patients in the trial with advanced multiple myeloma, 
14 patients showed a clinical benefit rate of 29% (Zeng, 2016). This preliminary data suggest 
that the combination of evofosfamide with dexamethasone is active in patients who have 
failed conventional therapy for the treatment of multiple myeloma.  
In addition to the phase II multiple myeloma trial, a phase I study investigating the 
clinical activity of evofosfamide for the treatment of patients with relapsed leukaemia 
(NCT01149915) demonstrated that evofosfamide as a single agent has activity in heavily pre-
treated leukaemia patients. To characterise the extent of the hypoxic bone environment in 
these leukaemia patients, this study also incorporated the hypoxia markers HIF-1a and CAIX, 
which were highly expressed in leukemic bone marrow and were significantly reduced after 
evofosfamide therapy (Badar et al., 2016). 
Although both multiple myeloma and leukaemia are defined as blood cancers, the 
bone marrow microenvironment promotes the growth of these cancer types, which ultimately 
leads to bone destruction and resistance to conventional therapies (Hideshima, Mitsiades, 
Tonon, Richardson, & Anderson, 2007). Therefore based on these phase I and II trials and 
preclinical data that investigated evofosfamide for the treatment of various types of cancer 
that occurs in the bone, patients with these bone cancers may benefit from evofosfamide 
therapy. In addition as indicated in the preclinical studies conducted as part of this thesis, 
evofosfamide may also have a potential role in the treatment of osteosarcoma and metastatic 
breast cancer. This will require further preclinical studies with more osteosarcoma and breast 
cancer cell lines in order to generate enough evidence to warrant future clinical trials 
investigating evofosfamide against osteosarcoma and metastatic breast cancer. 
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In addition to investiging the role of evofosfamide on osteosarcoma and metastatic 
breast cancer as outlined in this thesis, other cancer types that metastasize to the bone should 
also be investigated such as prostate, lung kidey and thyroid cancers. 
However there are limitations in the use of HAPs such as evofosfamide to target 
hypoxic regions in solid tumours and bone cancers, which may explain why evofosfamide 
failed to meet its primary endpoints in both phase III trials. Hypoxia between and within the 
tumour including in bone cancers is highly variable and is not always the cause of resistance 
to treatment. 
The use of direct and indirect hypoxia measuring factors in order to determine the 
levels of hypoxia have shown large variations of hypoxia between cancers within patients. 
These levels of hypoxia also determine the possibility of treatment failure by radiotherapy and 
conventional chemotherapy which are most effective in the normoxic regions of the tumour 
(Dhani et al., 2015; Milosevic et al., 2012). There have been no phase II and III clinical trials 
that have incorporated biomarkers that accurately measure hypoxia in patients. This would 
explain why some patients in these clinical trials had little benefit for HAPs as their tumours 
would have had very few areas of hypoxia (F. W. Hunter, Wouters, & Wilson, 2016). 
Secondly, not only is the efficacy of HAPs against cancer dependent on the levels of 
oxygen in hypoxic regions to activate the drug, but also the level of resistance of the cancer to 
the cytotoxic effector compound. Defining predictive biomarkers for HAPs in order to predict 
the efficacy of their effector drugs against tumours will determine their potential in the 
treatment of cancer. The dosing schedule of HAPs in combination with conventional 
chemotherapeutic agents will also be a contributing factor in determining tumour response 
while reducing side effects and allowing these drugs to complement each other (Lindsay, 
Garvey, Mumenthaler, & Foo, 2016).  
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Therefore biomarkers that can accurately detect and quantify the hypoxic tumour 
microenvironment as well as determining the tumour resistance against the effector compound 
are needed to determine the potential of HAPs in the treatment of cancer, including cancer in 
the bone. 
Taken together, despite the lack of success of HAPs in phase III clinical trials, HAP 
research and development has produced a wealth of knowledge, understanding and expertise 
leading to novel approaches in targeting hypoxia in the tumour and bone microenvironment 
which will implement the principles and experience gained from over 30 years of developing 
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